The identification of hydrophilic residues within the drug binding pocket in TMEM16F that are not conserved in other family members such as TMEM16A opens the door for the development of niclosamide analogs with better pharmacological properties that exclusively target TMEM16F for the treatment of severe COVID-19. Here, ANO6 is linked to COVID-19.